The Cancer Letter asked David Wholley, director of the Foundation for the National Institutes of Health Biomarker Consortium, to explain the novel scientific and administrative structure of Lung-MAP.
To access this subscriber-only content please log in or subscribe.
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe